Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Amrita Krishnan

Showing results (101-110 of 114) with videos related to

Pageof 12
Sort By:
Nature Medicine|August 31, 2023
Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myelomaHolly Lee, Sungwoo Ahn, Ranjan Maity, et al.
Lancet (London, England)|January 19, 2016
Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trialSagar Lonial, Brendan M Weiss, Saad Z Usmani, et al.
Blood|January 31, 2016
Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failurePaul G Richardson, Marcie L Riches, Nancy A Kernan, et al.
Frontiers in Immunology|September 20, 2021
Immune Recovery Following Autologous Hematopoietic Stem Cell Transplantation in HIV-Related Lymphoma Patients on the BMT CTN 0803/AMC 071 TrialPolina Shindiapina, Maciej Pietrzak, Michal Seweryn, et al.
The Lancet. Haematology|March 16, 2025
Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1-2 studyAjai Chari, Cyrille Touzeau, Carolina Schinke, et al.
Leukemia|August 12, 2020
International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trialsLuciano J Costa, Benjamin A Derman, Susan Bal, et al.
The Lancet. Haematology|February 3, 2022
Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working GroupNoopur S Raje, Elias Anaissie, Shaji K Kumar, et al.
The New England Journal of Medicine|June 6, 2022
Teclistamab in Relapsed or Refractory Multiple MyelomaPhilippe Moreau, Alfred L Garfall, Niels W C J van de Donk, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 3, 2017
Outcomes after Allogeneic Stem Cell Transplantation in Patients with Double-Hit and Double-Expressor LymphomaAlex F Herrera, Scott J Rodig, Joo Y Song, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 31, 2016
Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell TransplantationAlex F Herrera, Matthew Mei, Lawrence Low, et al.
Pageof 12

Showing results (101-110 of 114) with videos related to

Sort By:
Pageof 12
Nature Medicine|August 31, 2023
Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myelomaHolly Lee, Sungwoo Ahn, Ranjan Maity, et al.
Lancet (London, England)|January 19, 2016
Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trialSagar Lonial, Brendan M Weiss, Saad Z Usmani, et al.
Blood|January 31, 2016
Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failurePaul G Richardson, Marcie L Riches, Nancy A Kernan, et al.
Frontiers in Immunology|September 20, 2021
Immune Recovery Following Autologous Hematopoietic Stem Cell Transplantation in HIV-Related Lymphoma Patients on the BMT CTN 0803/AMC 071 TrialPolina Shindiapina, Maciej Pietrzak, Michal Seweryn, et al.
The Lancet. Haematology|March 16, 2025
Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1-2 studyAjai Chari, Cyrille Touzeau, Carolina Schinke, et al.
Leukemia|August 12, 2020
International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trialsLuciano J Costa, Benjamin A Derman, Susan Bal, et al.
The Lancet. Haematology|February 3, 2022
Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working GroupNoopur S Raje, Elias Anaissie, Shaji K Kumar, et al.
The New England Journal of Medicine|June 6, 2022
Teclistamab in Relapsed or Refractory Multiple MyelomaPhilippe Moreau, Alfred L Garfall, Niels W C J van de Donk, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 3, 2017
Outcomes after Allogeneic Stem Cell Transplantation in Patients with Double-Hit and Double-Expressor LymphomaAlex F Herrera, Scott J Rodig, Joo Y Song, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 31, 2016
Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell TransplantationAlex F Herrera, Matthew Mei, Lawrence Low, et al.
Pageof 12